Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Treasury Shares (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Treasury Shares for 9 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 24.13% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 24.13% year-over-year, with the annual reading at $5.1 million for FY2025, 24.13% up from the prior year.
  • Treasury Shares for Q4 2025 was $5.1 million at Denali Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Treasury Shares was $5.2 million in Q3 2025, with the low at $2.6 million in Q3 2021.
  • Average Treasury Shares over 5 years is $3.8 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Treasury Shares surged 64.78% in 2021, then rose 7.43% in 2024.
  • Over 5 years, Treasury Shares stood at $2.6 million in 2021, then increased by 26.64% to $3.3 million in 2022, then rose by 9.14% to $3.6 million in 2023, then grew by 13.57% to $4.1 million in 2024, then grew by 24.13% to $5.1 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $5.1 million, $5.2 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.